本文選題：大劑量 + 維生素C��； 參考：《中國(guó)藥房》2015年09期

【摘要】：目的:系統(tǒng)評(píng)價(jià)大劑量應(yīng)用維生素C治療相關(guān)疾病的安全性,以為臨床用藥提供循證參考。方法:計(jì)算機(jī)檢索Cochrane圖書(shū)館、EMBase、Pub Med、相關(guān)期刊論文、萬(wàn)方數(shù)據(jù)庫(kù)、中文科技期刊數(shù)據(jù)庫(kù),收集大劑量應(yīng)用維生素C治療相關(guān)疾病的臨床研究,提取資料并評(píng)價(jià)質(zhì)量后,采用R語(yǔ)言3.1.1版統(tǒng)計(jì)軟件對(duì)數(shù)據(jù)進(jìn)行Meta分析。結(jié)果:共納入23項(xiàng)研究,合計(jì)2 069例患者,共發(fā)生不良反應(yīng)540例。Meta分析結(jié)果顯示,針對(duì)有對(duì)照組的研究,維生素C治療組患者總體不良反應(yīng)發(fā)生率與對(duì)照組比較差異無(wú)統(tǒng)計(jì)學(xué)意義[RR=1.42,95%CI(0.92,2.20),P=0.382];針對(duì)所有納入研究,維生素C治療組患者的腹痛發(fā)生率為9%[95%CI(0.05,0.14)]、口干發(fā)生率為30%[95%CI(0.14,0.54)]、頭痛發(fā)生率為12%[95%CI(0.06,0.25)]、惡心發(fā)生率為25%[95%CI(0.13,0.44)]、腹瀉發(fā)生率為14%[95%CI(0.07,0.26)]。結(jié)論:大劑量應(yīng)用維生素C治療相關(guān)疾病的安全性較好,但應(yīng)注意消化系統(tǒng)的不良反應(yīng)。由于缺乏大樣本隨機(jī)對(duì)照試驗(yàn)(RCT)資料,且隨訪(fǎng)時(shí)間較短,該結(jié)論尚需要更多大樣本、多中心的RCT予以證實(shí)。
[Abstract]:Objective: to evaluate the safety of high-dose vitamin C in the treatment of related diseases and provide evidence-based reference for clinical use. Methods: the Cochrane library was searched with Cochrane library, including the full text database of Chinese journal, the database of Wanfang, the database of Chinese sci-tech periodicals, and the clinical research on the treatment of related diseases with high dose of vitamin C, the data were extracted and the quality was evaluated. The data were analyzed by Meta with R language version 3.1.1. Results: a total of 23 studies were included, totally 2 069 patients, 540 cases of adverse reactions. The results of Meta-analysis showed that there was a control group in the study. The overall incidence of adverse reactions in the vitamin C treatment group was not significantly different from that in the control group [RRN 1.42 95%]; The incidence of abdominal pain, dry mouth, headache, nausea and diarrhea were 9%, 30%, 12%, 25% and 14%, respectively. Conclusion: the high dose of vitamin C is safe for the treatment of related diseases, but the adverse reactions of digestive system should be paid attention to. Due to the lack of large sample randomized controlled trial data and the shorter follow-up time, this conclusion needs to be confirmed by multi-center RCT.
【作者單位】： 北京市結(jié)核病胸部腫瘤研究所;首都醫(yī)科大學(xué)附屬北京胸科醫(yī)院;
【分類(lèi)號(hào)】：R96

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 葉靖;陳弼滄;吳秋英;趙茜;陳國(guó)英;郭明玉;劉德桓;;中藥治療代謝綜合征臨床治療性文獻(xiàn)的系統(tǒng)評(píng)價(jià)[J];光明中醫(yī);2007年06期

2 衛(wèi)茂玲;劉鳴;李靜;張鳴明;;中國(guó)循證醫(yī)學(xué)/Cochrane中心2006～2008年全國(guó)系統(tǒng)評(píng)價(jià)培訓(xùn)班學(xué)員問(wèn)卷調(diào)查結(jié)果[J];中國(guó)循證醫(yī)學(xué)雜志;2009年02期

3 唐奇遠(yuǎn);何清;白冰;唐怡敏;唐尉;敖飛健;;肝蘇治療慢性乙型肝炎的系統(tǒng)評(píng)價(jià)[J];中國(guó)循證醫(yī)學(xué)雜志;2010年08期

4 李雨t，

本文編號(hào)：1929382